May 8th 2024
Renata Block, MMS, PA-C, shares her favorite topics from the aesthetic conference held last month.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Retinoic acid metabolism inhibitor causes less irritation
October 1st 2001Washington - A series of cutaneous pharmacology studies conductedwith a selective retinoic acid metabolism inhibitor suggest this novel compoundhas the potential for treating a variety of retinoid-responsive dermatologicdiseases but with the advantage of causing less irritation compared to retinoicacid, Gerard J. Gendimenico, Ph.D., said at the Society for InvestigativeDermatology meeting.